hidradenitis suppurativa
Conditions
Interventions
Secukinumab treatment group:None
Pesolimab treatment group:None
Sponsors
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age: 12 to 70 years old; 2. Clinically or pathologically diagnosed as hidradenitis suppurativa; 3. Voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who have received IL-12/23 or IL-23 inhibitors within 6 months before enrollment, any TNF inhibitor or IL-17A inhibitor within 3 months, physical therapy or systemic treatment (systemic antibiotics, retinoids, glucocorticoids, immunosuppressants, etc.) within 4 weeks, or topical medications (topical antibiotics, retinoids, etc.) within 2 weeks; 2. Patients with unclear primary disease diagnosis; 3. Patients with contraindications to the use of IL-17A or IL-36R inhibitors; 4. Patients with other active skin diseases that may affect disease assessment; 5. Pregnant women, lactating women, and those with plans to conceive within 1 year; 6. Patients with severe, uncontrolled systemic diseases, autoimmune diseases, malignant tumors, or infectious disease histories.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Hidradenitis Suppurativa Severity Score System (IHS4);Hidradenitis Suppurativa Clinical Response 50 (HiSCR50); | — |
Secondary
| Measure | Time frame |
|---|---|
| Numeric Rating Scale;DLQI, Dermatology Life Quality Index; | — |
Countries
China
Contacts
Public ContactChao Wu
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed